Allogene Therapeutics ALLO 深 滬
等待開盤 10-20 09:30:00 美东时间
1.23
-0.040
-3.15%
華盛通- 最 高1.27
- 今 開1.255
- 成交量 255.57万股
- 最 低 1.21
- 昨 收 1.27
- 總市值 2.69亿
- 52周最高 3.78
- 市盈率 靜 --
- 換手率 1.17%
- 52周最低 0.8621
- 委 比 21.43%
- 總股本 2.19亿
- 歷史最高 55.00
- 量 比 0.64
- 振 幅 4.72%
- 歷史最低 0.8621
- 每 手 1
- 風險率 0.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics announced on October 15, 2025, that its Compensation Committee granted stock option awards to 65 employees under the 2025 Inducement Plan. The awards total 1,093,300 shares with an exercise price of $1.49 per share, vesting over four years. Autolus is a biopharmaceutical company specializing in T cell therapies for cancer and autoimmune diseases. Contact: Amanda Cray at a.cray@autolus.com.
10-15 20:05
Allogene licensor Cellectis faces patent lawsuit in the U.S.
Cancer drug developer Allogene Therapeutics (NASDAQ:ALLO) announced on Tuesday that its licensor, Cellectis (NASDAQ:CLLS), is facing a lawsuit in the U.S. over allegations of patent infringement relat...
10-14 22:25
HYCROFT ANNOUNCES EXERCISE OF UNDERWRITERS' OVER-ALLOTMENT OPTION
WINNEMUCCA, Nev., Oct. 13, 2025 /PRNewswire/ -- Hycroft Mining Holding Corporation (Nasdaq: HYMC) ("Hycroft" or the "Company") announces, in connection with its previously announced public o...
10-14 05:30
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a comple...
10-10 21:53
JP Morgan Downgrades Allogene Therapeutics to Underweight
JP Morgan analyst Brian Cheng downgrades Allogene Therapeutics (NASDAQ:ALLO) from Neutral to Underweight.
10-10 19:38
Rivian Selects Agillence To Optimize Parts Logistics With Its Agillence Lean Logistics Optimizer Software
Agillence, Inc., an optimization company, today announced that Rivian Automotive, Inc. (NASDAQ:RIVN) has selected it to provide proprietary optimization software to support the planning of parts logistics
10-10 00:06
In Vivo与Allo CAR-T：谁先攻克商业化堡垒？
（来源：抗体圈） 2020年前后，同种异体CAR-T（AlloCAR-T）疗法风头无两。作为传统自体CAR-T的升级方向，它承诺摆脱“一人一药”的定制化...
09-22 18:46
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
Autolus Therapeutics announced the online publication of an abstract for their ACR Convergence 2025 poster presentation, showcasing updated data from the CARLYSLE study on obe-cel for severe refractory systemic lupus erythematosus (srSLE). The Phase I study demonstrates a manageable safety profile with no dose-limiting toxicities or severe CRS/ICANS, alongside reductions in SLEDAI-2K scores and clinical benefit in all patients, including complete...
09-16 12:05
Enlivex CEO Oren Hershkovitz Issues Shareholder Letter Highliting Phase IIa Topline Results For Allocetra In Knee Osteoarthritis And Clinical Development Roadmap
Dear fellow shareholders,I would like to take this opportunity to provide you with our perspective on our recent Phase IIa (ENX-CL-05-001) 3-month topline data readout for Allocetra™ in patients with
09-11 20:11
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
Allogene Therapeutics will participate in Citi's 2025 Biopharma Back to School Summit on September 3 at 7:30AM PT/10:30AM ET. Live webcasts and a replay will be available on the company's website under the Investors section. Allogene focuses on developing allogeneic CAR T products for cancer and autoimmune diseases to deliver scalable, ready-to-use cell therapies.
08-27 12:30
